Aurealis Pharma AG has closed a 5.6 million Swiss franc financing round. Headquartered in Basel and Finland, the biotechnology company develops medications for cancer and chronic inflammation.
Existing and new investors participated in the Series A financing round, including Swiss private investors as well as the Finnish funding agencies Finnerva and Tekes, announced Aurealis Pharma AG.
The company will use the new funding to advance the clinical development of AUP-16, a treatment for chronic wounds. It will also go toward accelerating research on the efficacy and safety of its cancer treatment AUP-5550.
The investors have deep confidence in Aurealis Pharma: “We find Aurealis Pharma to be a potential game-changer in the evolving chronic inflammation and cancer multitherapy landscape,” said Silvio Inderbitzin, one of the investors. Aurealis Pharma was founded in Kuopio, Finland in 2010. It has offices both there and in Basel.
